Generalized Anxiety Disorder (GAD) is characterized by persistent and exaggerated anxiety and worry about everyday life events with no apparent reasons for worry.
As per the Delveinsight, in 2017, the total 12-Month prevalent cases of Generalized Anxiety Disorder (GAD) in 7MM was 16,606,987.
The Generalized Anxiety Disorder (GAD) market size in the 7MM was USD 3,164 million in 2017.
Increasing awareness and prevalence and improved diagnostic criteria are the key drivers for the Generalized Anxiety Disorder (GAD) Market.
The key companies in the Generalized Anxiety Disorder (GAD) Market include Bionomics, Pherin Pharmaceuticals, VistaGen Therapeutics, Shire, and BioHaven Pharmaceuticals.
Source:
Generalized Anxiety Disorder (GAD) Market